Cargando…
17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial
BACKGROUND: Progestational agents may reduce the risk of preterm birth in women with various risk factors. We sought to test the hypothesis that a weekly dose of 17-hydroxyprogesterone caproate (17P) given to women with preterm rupture of the membranes (PROM) will prolong pregnancy and thereby reduc...
Autores principales: | Combs, C Andrew, Garite, Thomas J, Maurel, Kimberly, Mallory, Kimberly, Edwards, Rodney K, Lu, George, Porreco, Richard, Das, Anita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260323/ https://www.ncbi.nlm.nih.gov/pubmed/22206581 http://dx.doi.org/10.1186/1756-0500-4-568 |
Ejemplares similares
-
Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth
por: Sibai, Baha, et al.
Publicado: (2020) -
17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth – A Systematic Review and Meta-analysis Taking into Account the PROLONG Trial
por: Kuon, Ruben-J., et al.
Publicado: (2021) -
The Influence of Prior Obstetrical History on Current 17-Hydroxyprogesterone Caproate Use
por: Ransom, Carla E., et al.
Publicado: (2011) -
Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention
por: Garcia, Stephanie M., et al.
Publicado: (2021) -
Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?
por: Cohen, Gal, et al.
Publicado: (2022)